Clinical trials: Refractory Cancer, open to volunteers
T-cell Non-Hodgkin Lymphoma, Lymphoma, Extranodal NK-T-Cell
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients.
- Trial name
- RRTCLAlloSCT (NCT02859402)
- Testing
- Busulfan, Fludarabine
- Where
- 2 sites in South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Keimyung University Dongsan Medical Center
Hematologic Neoplasms
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Background: People with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high.
- Trial name
- NCT05327023
- Testing
- donor lymphocyte infusion, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Anaplastic Astrocytoma
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma
- Trial name
- NCT05956821
- Testing
- SIACI of cetuximab and bevacizumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Miami
Acute Leukemia, Acute Lymphoblastic Leukemia
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies).
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT04195633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell…
- Conditions
- Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT06928662
- Testing
- Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in…
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma Stage III, Multiple Myeloma Progression
- Trial name
- EPC-MM+L (NCT06485076)
- Testing
- Early Palliative Care
- Where
- Canada
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Ewing Sarcoma
RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT
The goal of this clinical research study is to learn if new anticancer drugs or drug combinations can help to control relapsed/refractory ES, DSRCT, or SRCS.
- Trial name
- NCT07781891
- Testing
- LX-101
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Myasthenia Gravis Generalized
PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease in which autoantibodies attack the neuromuscular junction, the site at which nerve cells communicate with muscle fibres, impairing signal transmission and causing fluctuating muscle…
- Trial name
- PANORAMA (NCT07717281)
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
This clinical trial tests a new mobile health application (app) called Planning Advance Care Together (PACT) to help people with cancer talk about and plan for advance care planning (the care they would want if they were unable…
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Hematologic Malignancy, Refractory Hematologic Malignancy
- Trial name
- NCT04515810
- Testing
- Internet-Based Intervention, Best Practice, Telephone-Based Intervention
- Where
- 4 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia (AML)
Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia
This is a clinical study on the use of iNK cells for the treatment of refractory relapsed acute myeloid leukemia.
- Trial name
- iNK-r/r AML (NCT06702098)
- Testing
- iNK cells
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Guangzhou Ruixin Biotechnological Co., LTD
Multiple Myeloma
Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Trial name
- NCT03196414
- Testing
- CART-138/BCMA/19/more
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
T-Cell and NK-Cell Neoplasm
A Global Study of the PETAL Consortium
The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or…
- Trial name
- PETAL (NCT06067347)
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Preleukemia, Myelodysplastic Neoplasm
Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS
This is a single-arm pilot study of the feasibility and safety of metformin in patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myelodysplastic neoplasms (LR-MDS).
- Conditions
- Preleukemia, Myelodysplastic Neoplasm, Cytopenia, Preleukemic Anemia
- Trial name
- NCT04741945
- Testing
- Metformin
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kirsten Grønbæk
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.
- Conditions
- Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
- Trial name
- NCT05595447
- Testing
- Brentuximab Vedotin 50 MG [Adcetris]
- Where
- Mexico
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospital Regional de Alta Especialidad del Bajio
AML/MDS, Acute Myeloid Leukemia
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia…
- Conditions
- AML/MDS, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT05986240
- Testing
- Danvatirsen, Danvatirsen + Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
AML (Acute Myeloid Leukemia), MDS/AML
Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
Safety and Feasibility of a Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation in AML, MDS/AML and Higher Risk MDS
- Conditions
- AML (Acute Myeloid Leukemia), MDS/AML, MDS (Myelodysplastic Syndrome)
- Trial name
- NCT07214064
- Testing
- RIC regimen
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute…
- Conditions
- Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
- Trial name
- SCOPE-L (NCT05237258)
- Testing
- Specialty Palliative Care, Primary Palliative Care
- Where
- 20 sites in United States
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma
This phase I trial tests the effect of allogeneic Orca-Q stem cell transplant in treating patients with high-risk multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous…
- Trial name
- NCT07759102
- Testing
- Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Relapsed/Refractory Small Cell Lung Cancer
This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.
This is a First-in-Human, open-label, early dose-escalation clinical study to evaluate the safety and preliminary efficacy of GC511B CAR T cell injection in Adult with DLL3+ r/r SCLC trial participants.
- Trial name
- NCT07249879
- Testing
- GC511B CAR-T Cell Injection
- Where
- 2 sites in China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Malignant Solid Tumors, Other Neoplasms Solid Tumors
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Background: Approximately 150 cases of cancer per one million per year are considered rare cancers. While all tumors originate from genetic changes, a small percentage of these tumors are familial.
- Conditions
- Malignant Solid Tumors, Other Neoplasms Solid Tumors, Pediatric Solid Tumor, Refractory Solid Tumors
- Trial name
- NCT03739827
- Where
- 3 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)